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Abstract 
The zebrafish is increasingly being adopted as an in vivo model of high 
throughput drug screening. In this brief review we outline the advantages and 
disadvantages of this approach and summarize recent screens that have 
attempted to identify novel small molecules with activity on the cardiovascular 
system. 
 
Introduction 
The zebrafish (Danio rerio) is a popular tropical pet fish that has been exploited 
for many years as a genetically tractable model of developmental biology [1]. 
Since the egg is fertilized after laying, zebrafish embryos develop externally to 
the mother, making them accessible for injection with genetic constructs or 
exposure to chemical treatment from the earliest stages. The near transparency 
of early embryos allows observation of organ development without the need for 
invasive manipulation. Tissue specific transgenics that express fluorescent 
reporters in the heart [2], endothelium [3,4] or blood [5] have allowed 
cardiovascular researchers to visualize cardiovascular development in a manner 
impossible using mammalian models. More recently, the zebrafish has been 
applied to drug discovery in attempts to identify small molecules with potential 
therapeutic effects. The first zebrafish based small molecule screen was 
published in 2000 [6], since when the results of at least fifty subsequent screens 
have been described. As with any model system, the zebrafish possesses 
advantages and disadvantages that must be appreciated when considering a 
zebrafish based small molecule screen, and we outline these below. 
 
Advantages of zebrafish screens 
The zebrafish boasts many advantages for drug screening. Fertile females lay 
several hundred eggs per week, which simply require incubation in medium to 
allow development until the onset of feeding at around 5 days post fertilization 
(dpf). Embryonic development proceeds rapidly; by 24 hours post fertilization 
(hpf) a recognizable vertebrate body plan is in place, with a primitive 
vasculature and a two chambered beating heart [7]. Embryos can be 
automatically dispensed into 96 well plates (generally 3-5 embryos/well) and 
survive in low volumes of liquid (100Pl). Robotic platforms allow rapid 
application of precise concentrations of small molecule libraries to the medium 
[8]. These generic features are common to almost all zebrafish-based screens, 
varying only in the developmental stage of embryo used, the libraries tested, and 
the zebrafish strain used. These may be transgenics, expressing a tissue specific 
fluorescent reporter in an organ of interest, mutants with a phenotype the screen 
aims to rescue or influence, or wildtype embryos, depending on the drug effect 
being sought. If modulation of expression of a known gene is the effect sought, 
whole mount in situ hybridization can be performed in an automated manner to 
assess expression of the target gene in hundreds of embryos in parallel. Figure 1 
shows a typical workflow for a zebrafish-based screen. Once   ǲǳ 
identified, rapid rescreening in different doses allows assessment of the drug 
effect in a more rigorous manner.  
 
Disadvantages of zebrafish screens ǡǯ ǲǳ
and false negatives. A good screen needs a reproducible, rapidly measurable 
endpoint with minimal variability, and ideally will include positive and negative 
controls that allow assessment of technical reliability. These considerations limit 
screens for physiological parameters such as blood flow that are highly variable 
in early embryos. Although the nature of the screen to some extent determines 
the throughput, in general at most only a few thousand molecules are tested per 
screen. This limitation means that most studies use libraries of molecules known 
to have some bioactive properties, rather than a truly unbiased screen as can be 
applied to in vitro screening efforts. Once a hit is identified in a zebrafish screen, 
its mechanism of action is not known, and this can cause difficulty in lead 
optimization and prediction of other, potentially harmful effects. Most screens 
test only a single concentration and this, coupled with unpredictable drug 
penetration, is likely to lead to a significant false negative rate. Although vascular 
delivery of drugs is possible via microinjection, this is technically challenging and 
unlikely to be scalable to a level that allows high throughput screening. Although 
the zebrafish and mammalian genomes are similar, levels of protein homology 
are generally low, and genome duplication in the fish has led to multiple 
zebrafish homologues of many human genes [9]. These features raise the 
possibility that a drug with effect in zebrafish may have no effect on the human 
homologue due to protein dissimilarity, while a drug that targets a human 
protein may have no effect on a duplicated zebrafish gene product due to 
duplication. It remains to be seen to what extent these disadvantages limit the 
ability of zebrafish -based drug discovery to identify therapeutic compounds for 
human use. 
 
Screening for drugs with novel cardiovascular effects in zebrafish 
Below, we summarize some recent screens that illustrate features of screen 
design and that have identified promising lead compounds; these are also 
summarized in Table 1. 
 
A zebrafish screen to identify anti-arrhythmics 
Long QT syndrome (LQTS) in humans predisposes to lethal cardiac arrhythmias 
and can be caused by genetic diseases or factors such as drugs. Such effects are a 
common cause of drug withdrawal after marketing when pro-arrhythmic effects 
become manifest [10]. 
To identify small molecules that shorten the QT interval, Peal et al exploited the 
breakdance zebrafish mutant [11]. This mutant, previously generated in a 
forward mutagenesis screen [12], suffers 2:1 AV block caused by QT 
prolongation induced by a mutation in the potassium channel KCNH2. Visual 
assessment of the embryos was used to assess whether this AV block was 
reversed by any of the small molecules examined. From 1200 drugs, 
Flurandrenolide and 2-methoxy-N-(4-methylphenyl) benzamide (2-MMB) 
rescued the 2:1 AV block phenotype. Both exert their function in a dose-
dependent manner by shortening repolarization time as evidenced by voltage-
sensitive optical mapping of ventricular action potential duration. These agents 
therefore may represent potential therapeutic strategies for the treatment of 
LQTS. 
 
Zebrafish screens to identify drugs for hyperlipidemia 
To identify compounds that inhibit dietary absorption of lipid, zebrafish embryos 
were fed the fluorescent phospholipid reporter PED-6, which is normally taken 
up and can be visualized in the gall bladder [13]. The ability of 3840 compounds 
to prevent this uptake was tested in 5dpf embryos exposed to test compounds 
prior to feeding. Embryos were examined by fluorescent stereomicroscopy for 
quantification of gall bladder fluorescence, and compounds that reduced this 
were considered as primary hits. This screen suffered from a significant false 
positive rate (1.1%) but was able to identify a number of compounds (whose 
identities were not revealed) that reliably prevented lipid uptake in rescreening 
and secondary screens.  
 
Zebrafish screens to identify drugs that modulate angiogenesis 
The earliest cardiovascular drug screens in zebrafish sought to identify agents 
that influence angiogenesis [14], and this remains the most frequent assay in 
more recent screens. The availability of endothelial specific transgenics, and the 
stereotypical and easily observed vascular development in zebrafish has made 
screening for such molecules particularly successful. Although early screens 
aimed to identify pan-angiogenesis inhibitors, later studies often aim to find 
drugs that preferentially affect specific vascular beds (see below). 
Xyloketals are natural compounds isolated from an endophytic fungus Xylaria sp. 
from the South China Sea [15] with vasorelaxant and angiogenic activities 
[16,17]. Xu et al. synthesised 21 novel xyloketal derivatives and tested their 
effect on angiogenesis in Fli1:GFP transgenic zebrafish that express GFP in the 
endothelium [17]. When the effect on the subintestinal vein was examined, 
several of these compounds induced increased branching of this vascular plexus, 
suggesting that they may promote angiogenesis. 
Arterial and venous angiogenesis are differentially regulated during 
embryogenesis. A recent screen aimed to identify compounds that selectively 
regulate these two processes [18]. The formation of the caudal vein plexus (CVP) 
in Fli1:GFP transgenics was used as a model for venous angiogenesis and the 
formation of primary intersegmental vessels (ISV) was used as the readout for 
arterial angiogenesis. From 469 compounds, the investigators found that 
aplexone preferentially suppresses venous angiogenesis while having no effect 
on primary ISV formation.  Aplexone was found to exert its effects via the HMG-
CoA pathway as evidenced by increased expression of several enzymes of this 
pathway and decreased cholesterol levels in aplexone-treated embryos. As a 
result of this, venous ECs exhibit defective posttranslational protein modification 
geranylgeranylation when treated with aplexone [19,20]. 
In keeping with the observation that some agents are able to disrupt 
angiogenesis in specific parts of the vasculature while having little effect on 
others, another group attempted to discover drugs that alter development of the 
embryonic zebrafish retinal vasculature while sparing angiogenesis elsewhere 
[21]. From 2000 molecules tested, five reproducibly caused specific changes in 
retinal vasculature; enalapril maleate, zearalenone, pyrogallin, albendazole and 
mebendazole. 
Supporting the important role of the HMG-CoA pathway in angiogenesis, a 
separate screen for small molecules that prevents ISV angiogenesis identified a 
number of HMG-CoA inhibitors (statins) as anti-angiogenic, leading to the ǯ
as an adjuvant to cancer therapy [22]. This is intriguing, given the 
epidemiological evidence suggesting that statins when taken for prevention of 
cardiovascular disease may confer some protection from cancer, although a 
definite link remains unproven [23]. 
A recent small screen of eleven compounds known to influence angiogenesis in 
other systems (recombinant vascular endothelial growth factor (VEGF), Tumour 
necrosis factor, Adalimumab, Infliximab, Bevacizumab, Oncostatin, Interleukin  ?Ⱦǡ ? ? ? ? ? ?Ȍalso used retinal angiogenesis as its primary assay 
[24]. Although the selective PI3 Kinase inhibitor LY294002 was shown to inhibit 
retinal angiogenesis in a dose-dependent manner with no effect on trunk 
vasculature, the other agents tested had no effect. Although this may seem 
surprising given the clear role of VEGF in angiogenesis, and the clear reduction in 
embryonic vascular development seen with VEGF knockdown or small molecule 
inhibition [25,26], peptides such as monoclonal antibodies or growth factors are 
unable to penetrate the embryo sufficiently to influence vascular development, 
and as such the zebrafish is unsuited for screening the effects of such molecules. 
Zebrafish screens are particularly well suited to assessment of natural products, 
which contain a diverse and poorly characterized combination of potentially 
bioactive molecules. In a screen of over 80 East African plant derived natural 
produces, extracts from Oxygonum sinuatum and Plectranthus barbatus were 
identified to have anti-angiogenic effect on ISV formation [27]. Once such an 
effect is detected, fractionation is required to identify which constituent is 
responsible for the biological effect.  
 
Zebrafish screens to identify drugs that modulate cardiac development 
Fibroblast growth factors (FGFs) play an important role in regulation of 
proliferation and embryonic development, exerting their effects via various 
signalling cascades including MAP/ERK kinases [28,29]. A transgenic reporter 
line for FGF that expresses GFP at sites of FGF activity was used in a small 
molecule screen to identify novel activators of FGF signalling [30]. From 5000 
compounds tested, one ((E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-
1H-inden-1-one, or BCI) increased fluorescence in a concentration-dependent 
manner. In keeping with the central role for FGF in cardiac development, BCI 
treatment led to an expansion of cardiac progenitor cells with expanded cardiac 
tissue. The expansion of cardiac progenitors was accompanied by diminished 
expression of blood and vascular markers [30]. 
 
Conclusion 
The slowing pace of new drug discovery has been well publicized [31], and 
remains in need of a solution. Until a drug that has been discovered in a zebrafish 
screen has been shown to possess clinical utility, the potential of zebrafish based 
screens to identify novel drugs remains unproven. Even if zebrafish screens are 
able to identify therapeutic moieties, given the relative infancy of this approach it 
is unrealistic to expect translation to clinical application for at least five years. 
Nevertheless, even without such a breakthrough, the screens so far conducted 
have allowed novel insights into disease related mechanisms and pathways. The 
increasing rate of publication of zebrafish-based screens suggests a growing 
acceptance of the technology and increasing momentum for its utilization in drug 
discovery efforts. 
  
  
 
Figure 1 
Generic workflow for small molecule screen in zebrafish showing the major 
steps involved from mating the adult zebrafish and collecting the embryos, 
followed by distribution of the embryos into 96 well plates and the addition of 
libraries of small molecules to screen. The end assay varies according to the 
effect sought, but frequently examines vascular development using transgenic 
embryos, or specific vascular gene expression assessed by in situ hybridization. 
 
Reference Effect sought Drug 
libraries 
used 
Drugs 
tested 
Concn 
used 
Zebrafish 
strains used 
Stage drug 
added 
Stage 
screened 
 
Assay Compounds identified 
[11] chemical 
suppressors of LQT 
Syndrome 
Prestwick, 
Illkirch, France 
and 
Chembridge 
1200 10ng/µ
L 
Breakdance 48hpf 72hpf  visual screen for 
the presence of 2:1 
AV block 
Flurandrenolide and 2-methoxy-N-(4-
methylphenyl) benzamide (2-MMB) 
[13] inhibitors of lipid 
absorption  
MLSCN 3840 25µM WT 5dpf 6dpf qualitative visual 
assessment of 
gallbladder 
fluorescence   
Not revealed 
[17] angiogenic activities 
of newly designed 
xyloketal derivatives 
Newly 
synthesized 
xyloketal 
derivatives (1-
21) 
21 100µM Tg(fli1:EGFP)  6hpf 78hpf visual screen for the 
presence of ectopic 
subintestinal veins  
(SIV) branches 
Xyloketals 2,3,4,5,8,9,12-16,19,20 
and 22 
[18] compounds 
selectively 
suppressing arterial 
and venous 
angiogenesis 
Biomol 
International 
(300 
compounds), 
synthetic 
chemical library 
468 10µM Tg(kdrl:GFP)la116 4-24hpf 48hpf visual assay 
(confocal imaging) 
of ISV and caudal 
vein plexus 
angiogenesis 
aplexone 
[21] compounds 
affecting vascular 
development in 
zebrafish retina 
Spectrum 
Collection 
approx. 
2000 
10µM Tg(fli1:EGFP)  24hpf 
corresponding 
to 20 somite 
stage (19hpf) 
and 68hpf 
corresponding 
to pectoral fin 
stage (68hpf) 
respectively 
1-6dpf  visual screen for 
morphological 
abnormalities in 
retinal vessel 
development 
enalapril maleate, zearalenone, 
pyrogallin, albendazole and 
mebendazole 
[22] Angiogenesis 
inhibitors 
Spectrum 
Collection  
2000 10µM Tg(flk1:EGFP)  20hpf 52hpf quantitative visual 
screen for inhibition 
of ISV angiogenesis 
simvastatin, mevastatin, lovastatin, 
rosuvastatin, isorotenone, 
dihydromunduletone and aristocholic 
acid 
[24] inhibitors of retinal 
angiogenesis  
compounds 
known to affect 
angiogenesis 
11 various  Tg(flk1:EGFP)  24hpf 5dpf quantitative visual 
screen for the 
number of primary 
branches of hyaloid 
retinal vessels 
LY294002 (PI3 kinase inhibitor) 
 
[27] medicinal plants for 
angiogenesis 
inhibitors 
methanolic 
extracts from 
east African 
medicinal 
plants 
over 80 various  Tg(fli1:EGFP)  16hpf 40hpf visual screen for the 
inhibition of ISV 
angiogenesis 
6-methyl-1,3,8-
trihydroxyanthraquinone (emodin) 
and coleon A lactone (C20H19O6) 
[30] activators of FGF 
signalling cascade, 
to study the role of 
FGF signalling in 
embryonic heart 
development 
NCI diversity set 
(NCI/NIH), 
Natural 
Products library 
(MicroSource 
Discovery 
Systems 
Inc.),Phosphata
se targted set 
(ChemDiv Inc.) 
5000 10µM Tg(dusp6:EGFP)pt6 24hpf 30hpf visual screen for 
reporter 
fluorescence  
BCI ((E)-2-benzylidene-3-
(cyclohexylamino)-2,3-dihydro-1H-
inden-1-one) 
[32] biological activity of 
newly synthesized 
retinoic acid 
analogues 
22 novel 
retinoid acid 
analogues 
22 10µM hybrid of AB and TU 
WT  
5hpf 24hpf visual screen for 
morphological 
alterations such as 
disruption of the 
body axis 
retinoic acid analogue BT10  
 
 
Table 1. Summary of recent cardiovascular screens. WT: wildtype, hpf: hours post fertilization, dpf: days post fertilization, ISV: 
intersegmental vessels, AV block: atrioventricular block, LQT Syndrome: long QT Syndrome,
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